XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Statement Of Stockholder's Equity - USD ($)
Total
Class A Common Stock
Additional Paid-In Capital
Accumulated other comprehensive Income
Accumulated Deficit
Balance, shares at Jun. 30, 2023   37,344,739      
Balance, amount at Jun. 30, 2023 $ 35,952,525 $ 373,447 $ 242,808,771 $ 606,536 $ (207,836,229)
Employee Stock Purchase Plan, shares   14,607      
Employee Stock Purchase Plan, amount 19,719 $ 146 19,573 0 0
Exercise of Stock Options, RSUs & RSAs, net shares   14,482      
Exercise of Stock Options, RSUs & RSAs, net amount 0 $ 145 (145) 0 0
Issuance of common stock for acquisition of Visimid, shares   81,610      
Issuance of common stock for acquisition of Visimid, amount 150,000 $ 816 149,184 0 0
Stock-based compensation on stock options, RSUs & RSAs 240,075 0 240,075 0 0
Foreign currency translation adjustment (125,208) 0 0 (125,208) 0
Net Income (Loss) (1,342,376) $ 0 0 0 (1,342,376)
Balance, shares at Sep. 30, 2023   37,455,438      
Balance, amount at Sep. 30, 2023 34,894,735 $ 374,554 243,217,458 481,328 (209,178,605)
Balance, shares at Jun. 30, 2023   37,344,739      
Balance, amount at Jun. 30, 2023 35,952,525 $ 373,447 242,808,771 606,536 (207,836,229)
Foreign currency translation adjustment 134,765        
Net Income (Loss) (3,056,039)        
Balance, shares at Dec. 31, 2023   37,549,378      
Balance, amount at Dec. 31, 2023 33,699,736 $ 375,494 243,475,209 741,301 (210,892,268)
Balance, shares at Sep. 30, 2023   37,455,438      
Balance, amount at Sep. 30, 2023 34,894,735 $ 374,554 243,217,458 481,328 (209,178,605)
Exercise of Stock Options, RSUs & RSAs, net shares   93,940      
Exercise of Stock Options, RSUs & RSAs, net amount 0 $ 940 (940) 0 0
Stock-based compensation on stock options, RSUs & RSAs 258,691 0 258,691 0 0
Foreign currency translation adjustment 259,973 0 0 259,973 0
Net Income (Loss) (1,713,663) $ 0 0 0 (1,713,663)
Balance, shares at Dec. 31, 2023   37,549,378      
Balance, amount at Dec. 31, 2023 33,699,736 $ 375,494 243,475,209 741,301 (210,892,268)
Balance, shares at Jun. 30, 2024   39,254,643      
Balance, amount at Jun. 30, 2024 30,199,665 $ 392,546 245,140,758 509,936 (215,843,575)
Employee Stock Purchase Plan, shares   8,232      
Employee Stock Purchase Plan, amount 10,372 $ 82 10,290 0 0
Exercise of Stock Options, RSUs & RSAs, net shares   70,309      
Exercise of Stock Options, RSUs & RSAs, net amount 0 $ 703 (703) 0 0
Issuance of common stock for acquisition of Visimid, shares   279,553      
Issuance of common stock for acquisition of Visimid, amount 321,358 $ 2,796 318,562 0 0
Stock-based compensation on stock options, RSUs & RSAs 264,475 0 264,475 0 0
Foreign currency translation adjustment 271,594 0 0 271,594 0
Net Income (Loss) (1,622,745) $ 0 0 0 (1,622,745)
Balance, shares at Sep. 30, 2024   39,612,737      
Balance, amount at Sep. 30, 2024 29,444,719 $ 396,127 245,733,382 781,530 (217,466,320)
Balance, shares at Jun. 30, 2024   39,254,643      
Balance, amount at Jun. 30, 2024 30,199,665 $ 392,546 245,140,758 509,936 (215,843,575)
Foreign currency translation adjustment (179,441)        
Net Income (Loss) (4,234,742)        
Balance, shares at Dec. 31, 2024   39,890,834      
Balance, amount at Dec. 31, 2024 26,702,938 $ 398,908 246,051,852 330,495 (220,078,317)
Balance, shares at Sep. 30, 2024   39,612,737      
Balance, amount at Sep. 30, 2024 29,444,719 $ 396,127 245,733,382 781,530 (217,466,320)
Exercise of Stock Options, RSUs & RSAs, net shares   229,097      
Exercise of Stock Options, RSUs & RSAs, net amount 0 $ 2,291 (2,291) 0 0
Stock-based compensation on stock options, RSUs & RSAs 231,581 0 231,581 0 0
Foreign currency translation adjustment (451,035) 0 0 (451,035) 0
Net Income (Loss) (2,611,997) $ 0 0 0 (2,611,997)
Shares issued as compensation, shares   49,000      
Shares issued as compensation, amount 89,670 $ 490 89,180 0 0
Balance, shares at Dec. 31, 2024   39,890,834      
Balance, amount at Dec. 31, 2024 $ 26,702,938 $ 398,908 $ 246,051,852 $ 330,495 $ (220,078,317)